This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-06-1057v1 66/21/10630    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kjaer, S. Articles by Iftner, T. Search for Related Content PubMed PubMed Citation Articles by Kjaer, S. Articles by Iftner, T.

The Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus–Positive, Cytologically Normal Women Over a 10-Year Period

¹ Institute of Cancer Epidemiology, Danish Cancer Society; ² The Juliane Marie Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; ³ Laboratory for Pathology and Medical Microbiology, PAMM Laboratories, Eindhoven, the Netherlands; ⁴ Department of Pathology, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; ⁵ Digene Corp., Gaithersburg, Maryland; and ⁶ Sektion Experimentelle Virologie, Universitaetsklinikum Tuebingen, Tuebingen, Germany

Requests for reprints: Susanne Kjaer, Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, DK-2100, Copenhagen, Denmark. Phone: 45-3525-7663; E-mail: susanne{at}cancer.dk.

In spite of the success of cervical cytology as a cancer-screening tool, it has important limitations, and human papillomavirus (HPV) testing may be valuable in future screening. The majority of women in screened populations, who test HPV positive, will have a concurrent normal smear, and we need more information about the risk for subsequent high-grade cervical lesions in these women. We examined 8,656 younger women (22–32 years old) and 1,578 older women (40–50 years old) who were followed for development of cervical neoplasia (cytology and/or histology) through the Danish Pathology Data Bank. We estimated the proportion of women developing cervical lesions of different types before a given time point as a function of time. Among women with normal cytology and positive high-risk Hybrid Capture 2 (HC2) test, 17.7% and 24.5% of younger and older women, respectively, had a subsequent abnormal Pap smear within 5 years. The risk of CIN3 or cancer within 10 years among younger women with positive HC2 test was 13.6% (10.9–16.2) and 21.2% (2.7–36.1) among older women. An analysis among younger women also being HC2-positive 2 years before baseline showed a subsequent 10-year risk of CIN3 of 18% (14.6–21.5). Among older women where HPV may be added to general screening, the estimated absolute risk of CIN3 in HC2-positive women was more than 20% within 10 years. These results indicate that even a single positive HPV test in cytologically negative women is substantially predictive of high-grade CIN and suggest that HC2 testing can help stratify women into different risk categories. (Cancer Res 2006; 66(21): 10630-6)

This article has been cited by other articles:

				P. E Castle, A. C. Rodriguez, R. D Burk, R. Herrero, S. Wacholder, M. Alfaro, J. Morales, D. Guillen, M. E Sherman, D. Solomon, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study BMJ, July 28, 2009; 339(jul28_2): b2569 - b2569. [Abstract] [Full Text] [PDF]

				C. Porras, A. C. Rodriguez, A. Hildesheim, R. Herrero, P. Gonzalez, S. Wacholder, R. D. Burk, and M. Schiffman Human Papillomavirus Types by Age in Cervical Cancer Precursors: Predominance of Human Papillomavirus 16 in Young Women Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 863 - 865. [Abstract] [Full Text] [PDF]

				P. E. Castle Invited Commentary: Is Monitoring of Human Papillomavirus Infection for Viral Persistence Ready for Use in Cervical Cancer Screening? Am. J. Epidemiol., July 15, 2008; 168(2): 138 - 144. [Abstract] [Full Text] [PDF]

				P. E. Gravitt, M. Schiffman, D. Solomon, C. M. Wheeler, and P. E. Castle A Comparison of Linear Array and Hybrid Capture 2 for Detection of Carcinogenic Human Papillomavirus and Cervical Precancer in ASCUS-LSIL Triage Study Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1248 - 1254. [Abstract] [Full Text] [PDF]

				P. E. Castle, P. E. Gravitt, D. Solomon, C. M. Wheeler, and M. Schiffman Comparison of Linear Array and Line Blot Assay for Detection of Human Papillomavirus and Diagnosis of Cervical Precancer and Cancer in the Atypical Squamous Cell of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion Triage Study J. Clin. Microbiol., January 1, 2008; 46(1): 109 - 117. [Abstract] [Full Text] [PDF]

				M. P. Stevens, S. M. Garland, E. Rudland, J. Tan, M. A. Quinn, and S. N. Tabrizi Comparison of the Digene Hybrid Capture 2 Assay and Roche AMPLICOR and LINEAR ARRAY Human Papillomavirus (HPV) Tests in Detecting High-Risk HPV Genotypes in Specimens from Women with Previous Abnormal Pap Smear Results J. Clin. Microbiol., July 1, 2007; 45(7): 2130 - 2137. [Abstract] [Full Text] [PDF]

				P. E. Castle, J. Dockter, C. Giachetti, F. A.R. Garcia, M. K. McCormick, A. L. Mitchell, E. B. Holladay, and D. P. Kolk A Cross-sectional Study of a Prototype Carcinogenic Human Papillomavirus E6/E7 Messenger RNA Assay for Detection of Cervical Precancer and Cancer Clin. Cancer Res., May 1, 2007; 13(9): 2599 - 2605. [Abstract] [Full Text] [PDF]